Soros Fund Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Soros Fund Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-2,700	Closed	-$626K	–	295
2015 Q1	$626K	Hold	2,700	–	–	0.01%	211
2014 Q4	$622K	Buy	+2,700	New	+$579K	0.01%	181

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Soros Fund Management's BLCM Position: Q2 2015 in Review

Soros Fund Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2015, closing a stake of 2,700 shares — an estimated $626K sold.

Soros Fund Management first reported a position in BLCM in Q4 2014 and held it in 2 quarters. The position peaked at $626K in Q1 2015. 81 funds tracked by Wall St. Rank hold BLCM as of Q2 2015.

Soros Fund Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
Soros Fund Management sold 2,700 Bellicum Pharmaceuticals, Inc. shares in Q2 2015, an estimated $626K.
Soros Fund Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
Soros Fund Management's Bellicum Pharmaceuticals, Inc. position peaked at $626K in Q1 2015.
81 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2015.

Based on Soros Fund Management's 13F filing for Q2 2015, filed 14 Aug 2015.